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Abstract: Deficiency of antiquitin (ATQ), an enzyme involved in lysine degradation, is the major cause of
vitamin B6 -dependent epilepsy. Accumulation of the potentially neurotoxic ￿-aminoadipic semialdehyde
(AASA) may contribute to frequently associated developmental delay. AASA is formed by ￿-aminoadipic
semialdehyde synthase (AASS) via the saccharopine pathway of lysine degradation, or, as has been
postulated, by the pipecolic acid (PA) pathway, and then converted to ￿-aminoadipic acid by ATQ. The
PA pathway has been considered to be the predominant pathway of lysine degradation in mammalian
brain; however, this was refuted by recent studies in mouse. Consequently, inhibition of AASS was
proposed as a potential new treatment option for ATQ deficiency. It is therefore of utmost importance
to determine whether the saccharopine pathway is also predominant in human brain cells. The route
of lysine degradation was analyzed by isotopic tracing studies in cultured human astrocytes, ReNcell
CX human neuronal progenitor cells and human fibroblasts, and expression of enzymes of the two lysine
degradation pathways was determined by Western blot. Lysine degradation was only detected through
the saccharopine pathway in all cell types studied. The enrichment of 15 N-glutamate as a side product
of AASA formation through AASS furthermore demonstrated activity of the saccharopine pathway. We
provide first evidence that the saccharopine pathway is the major route of lysine degradation in cultured
human brain cells. These results support inhibition of the saccharopine pathway as a new treatment
option for ATQ deficiency.
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Abstract
Deficiency of antiquitin (ATQ), an enzyme involved in lysine degradation, is the
major cause of vitamin B6-dependent epilepsy. Accumulation of the potentially
neurotoxic α-aminoadipic semialdehyde (AASA) may contribute to frequently
associated developmental delay. AASA is formed by α-aminoadipic semialdehyde
synthase (AASS) via the saccharopine pathway of lysine degradation, or, as has
been postulated, by the pipecolic acid (PA) pathway, and then converted to
α-aminoadipic acid by ATQ. The PA pathway has been considered to be the pre-
dominant pathway of lysine degradation in mammalian brain; however, this was
refuted by recent studies in mouse. Consequently, inhibition of AASS was pro-
posed as a potential new treatment option for ATQ deficiency. It is therefore of
utmost importance to determine whether the saccharopine pathway is also predomi-
nant in human brain cells. The route of lysine degradation was analyzed by isotopic
tracing studies in cultured human astrocytes, ReNcell CX human neuronal progeni-
tor cells and human fibroblasts, and expression of enzymes of the two lysine degra-
dation pathways was determined by Western blot. Lysine degradation was only
detected through the saccharopine pathway in all cell types studied. The enrich-
ment of 15N-glutamate as a side product of AASA formation through AASS fur-
thermore demonstrated activity of the saccharopine pathway. We provide first
evidence that the saccharopine pathway is the major route of lysine degradation in
cultured human brain cells. These results support inhibition of the saccharopine
pathway as a new treatment option for ATQ deficiency.
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1 | INTRODUCTION
Lysine degradation has been considered to have two distinct
pathways, through saccharopine formation by ε-deamination,
or through pipecolic acid (PA) formation by α-deamination
or transamination (Figure 1), although the first enzyme of the
PA pathway has not yet been identified.1 Both proposed path-
ways lead to formation of Δ1-piperideine-6-carboxylate
(P6C) and its open form α-aminoadipic semialdehyde
(AASA), which is then converted to α-aminoadipic acid
(AAA) by the AASA dehydrogenase antiquitin (ATQ).
Based on rat and mouse studies, it has long been believed that
the PA pathway is predominant in the brain, while in other
tissues the saccharopine pathway is more active.1–5
In ATQ deficiency, the most frequent cause of vitamin
B6/pyridoxine-dependent epilepsy, AASA and P6C accumu-
late, leading to inactivation of pyridoxal 50-phosphate (PLP),
the active vitamer of vitamin B6. This occurs due to a con-
densation reaction between PLP and accumulated P6C.6
Despite seizure control and reduction of AASA with high-
dose vitamin B6 (pyridoxine) treatment, around 70% of
ATQ-deficient patients still suffer from developmental
delay.6 This could be due to AASA, which is highly reactive
and possibly neurotoxic and which levels do not
normalize.7–11
In the search for new treatment modalities, the lysine deg-
radation pathway has gained new attention and the activity of
the PA pathway has been brought into question by recent iso-
topic tracing studies. In fibroblasts from ATQ-deficient
patients, PA derived only from the saccharopine pathway.5
PA formation by the saccharopine pathway was demonstrated
via conversion of P6C to PA by pyrroline-5-carboxylate
reductase (P5CR),12 in contrast to the previous assumption
that PA is exclusively produced by the PA pathway. It was
also recently shown that in mouse brain, liver, and kidney,
lysine is not degraded to AAA by the PA pathway but only
through the saccharopine pathway.13,14 Development of inhib-
itors of α-aminoadipic semialdehyde synthase (AASS), the
enzyme which converts lysine to saccharopine, was proposed
as a possible new treatment strategy in patients with ATQ
deficiency.13,14 As any activity through the PA pathway could
result in accumulation of AASA/P6C even if AASS is inhib-
ited, it is important to determine whether the saccharopine
pathway is also the major lysine degradation pathway in
human brain, as the lysine degradation pathways appear to
show species-specific activities.15–19,33
In this study, we used isotopic tracing studies to examine
whether in human brain cells, AAA is formed by the PA path-
way as has been deduced from previous studies, or by the sac-
charopine pathway as was recently demonstrated in mouse
brain. It has been shown that ATQ is expressed in human
astrocytes but not in neurons20; therefore, we examined the
formation of AAA in astrocytes as well as in a human neural
progenitor cell (NPC) line derived from the cortical region of
human fetal brain (ReNcell CX NPCs), which we demonstrate
express AASS and ATQ. In addition, we examined whether
activity through the PA pathway might increase when the sac-
charopine pathway is impaired, by comparing AASS-deficient
and ATQ-deficient human fibroblasts to control fibroblasts.
2 | METHODS
2.1 | Cell culture
Human fibroblasts (Life Technologies, Carlsbad, California,
US), human astrocytes derived from human cortex (Sciencell
Research Laboratories, Carlsbad, California, US), and ReNcell
CX humanNPCs (Millipore, Billerica,Massachusetts) were cul-
tured according to the manufacturers' directions. Astrocytes
were cultured for a maximum of 10 population doublings (four
passages). ATQ-deficient fibroblasts were provided by
B. Plecko and P.Mills (Institute of Child Health, University Col-
lege London with Great Ormond Street Hospital for Children,
National Health Service Trust, London, UK) and were previ-
ously characterized.6 AASS-deficient fibroblasts were provided
by J. Haeberle (Division of Metabolism, University Children's
Hospital Zurich, Zurich, Switzerland) and have been previously
described.21 Deficiency of ATQ and AASS was shown by
Western blot analysis (Figure S1), confirming the previously
reported deleterious effects of mutations in these cells.6,21
2.1.1 | Tracing experiments with 15N-labeled
lysine
Cells were incubated for 24 hours in custom lysine-free media
(Gibco, ThermoFisher Scientific, Waltham, MA USA) supple-
mented with L-[α15N]-lysine (α15N-Lys) (Cambridge Isotope
Laboratories) or L-[ε15N]-lysine (ε15N-Lys) (Sigma-Aldrich,
St. Louis, Missouri, USA) or unlabelled lysine to a final con-
centration of 0.44 g/L (Sigma-Aldrich).
Specifically, astrocytes were incubated in astrocyte media
made from custom lysine-free Dubelcos modified Eagle





































































FIGURE 1 Lysine degradation pathway. The proposed pathways of lysine degradation through the PA pathway via α-deamination (dotted
blue line) and the saccharopine pathway via ε-deamination (orange line), both leading to the formation of AASA/P6C and conversion of AASA to
AAA. AAA, α-aminoadipic acid; AADAT/KAT2, kynurenine/alpha-aminoadipate aminotransferase; AASS, alpha-aminoadipic semialdehyde
synthase; ATQ, antiquitin (α-aminoadipic semialdehyde dehydrogenase); CRYM/KR, μ-crystallin/ketimine reductase; P5CR, pyrroline-
5-carboxylate reductase; P6C, Δ1-piperideine-6-carboxylate; PA, pipecolic acid; PIPOX, pipecolic acid oxidase
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medium (DMEM) supplemented with N2 supplement and
one-shot Fetal bovine serum (FBS) (Gibco, ThermoFisher
Scientific). ReNcell CX NPCs were incubated in custom
lysine-free DMEM-F12 (3: 1) (Gibco, ThermoFisher Scien-
tific) supplemented with B27 (2%), heparin (10 Units/ml,
Sigma), fibroblast growth factor (FGF) (20 ng/mL), and epi-
dermal growth factor (EGF) (20 ng/mL) for labeled lysine
experiments, instead of ReNcell neural stem cell (NSC)
media supplemented with FGF (20 ng/mL), and EGF
(20 ng/mL), which was used for routine culture. Fibroblasts
were incubated in custom lysine-free DMEM (Gibco, Ther-
moFisher Scientific) supplemented with 5% fetal calf serum
(FCS) for labeled lysine experiments, rather than DMEM
supplemented with 10% FCS as was used for routine culture.
2.1.2 | Cell harvesting and sample
preparation for liquid chromatography-mass
spectrometry
The volume of cell lysates analyzed was normalized by
Hoescht assay as described previously22 to account for dif-
ferences in efficiency of cell transfer during harvesting
(Supplementary Information). Cells were washed three times
with ddH20, then scraped using a rubber scraper into 50%
methanol (Sigma-Aldrich). Cell extracts were sonicated for
15 sec then centrifuged at 14,500 g at 4 C for 15 min. The
supernatant was evaporated in a Concentrator Plus
(Eppendorf) and resuspended in 10 μL of 50% methanol.
2.2 | Quantitative and qualitative analysis of
PA, P6C, AASA, and AAA
The quantitative analysis of PA, P6C, AASA, AAA, and their
respective labeled-ions (15N-PA, 15N-P6C, 15N-AASA, and
15N-AAA) in cell lysates and cell culture media was performed
using a liquid chromatography-mass spectrometry (LC-
MS/MS) system (Thermo Ultra High Performance Liquid
Chromatography [UHPLC] Ultimate 3000XRS coupled to an
SCIEX 5500 TripleQuad) with modifications of published pro-
tocols5,23 (Supplementary Information). For all metabolites,
the limit of detection and the limit of quantification were esti-
mated at 0.004 μM (S/N = 3) and 0.013 μM (S/N = 10),
respectively. Enrichment of 15N-metabolites was expressed as
molar percent enrichment (MPE), as described previously.5
The quantification limit of MPE was calculated as <5%.
Qualitative analysis of lysine, PA, AAA, glutamate, and
glutamine, as well as their isotopically labeled analogues
was performed using an alternative UHPLC-MS/MS
approach (Hydrophilic Interaction Liquid Chromatography
[HILIC] chromatography utilizing a Thermo UHPLC Ulti-
mate 3000XRS coupled to a QExactive high-resolution mass
spectrometer, Supplementary Information).
2.3 | Western blot analysis
Western blots were performed following standardized proce-
dures as described in the Supplementary Information. Pri-
mary antibodies and dilutions used were ATQ (1:50000;
Abcam, Cambridge, UK), PA oxidase (PIPOX) (1:2000;
Sigma-Aldrich, Buchs SG, Switzerland), AASS (1:2000;
Abcam), and β-Actin (1:10000; Abcam). All procedures fol-
lowed were in accordance with the ethical standards of the
responsible committee on human experimentation (institu-
tional and national) and with the Helsinki Declaration of
1975, as revised in 2000. Informed consent was obtained
from the legal guardians of the three patients who provided
the fibroblasts for this study.
3 | RESULTS
3.1 | Expression of enzymes and activity of the
PA and saccharopine pathway in cultured
human cells
Western blot analysis showed that the enzymes ATQ,
PIPOX, and AASS are expressed in human astrocytes,
NPCs, and fibroblasts (Figure 2A).
In cultivated human astrocytes, NPCs, and fibroblasts,
we detected lysine degradation through the saccharopine
pathway and not the PA pathway, using isotopic tracing
studies with L-[α15N]-lysine (α15N-Lys) and L-[ε15N]-lysine
(ε15N-Lys). 15N-labeled lysine degradation products were
only detected in cells supplemented with α15N-Lys and not
in cells grown with ε15N-Lys (Figure 2B).
15N-labeled AAA was detected in astrocytes, NPCs, and
fibroblasts only when the media was supplemented with
α15N-Lys, as shown by 40%-60% MPE of 15N-labeled AAA
(Figure 2B). The same results were also seen in human neu-
ral stem cells derived from human embryonic stem cells
(hESCs) (Gibco, ThermoFisher Scientific) with 44% MPE of
15N-labeled AAA in cells supplemented with α15N-Lys
(Figure S2). The 40%-60% MPE of 15N-labeled AAA indi-
cates that approximately half AAA was unlabelled, which is
likely due to isotopic scrambling during the reversible,
transaminase-induced conversion of AAA and α-ketoglutaric
acid to α-ketoadipic acid and glutamate. In contrast, 15N-
labeled AAA was below the quantification limit (5% MPE)
in cells grown in ε15N-Lys, indicating that no PA pathway-
derived AAA was detectable.
In astrocytes, low concentrations of AASA/P6C and PA
were measured (close to the detection limit), derived exclu-
sively from the saccharopine pathway (80%-100% MPE with
α15N-Lys, Figure S3). In NPCs, no AASA/P6C or PA was
detected in cells incubated with lysine, and in fibroblasts, no
AASA/P6C and low levels of PA were measured, only derived
from the saccharopine pathway (50% MPE with α15N-Lys,
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Figure S3). In cell culture media from astrocytes, NPCs and
fibroblasts, labeled PA was detected, only from cells supple-
mented with α15N-Lys and not ε15N-Lys (Figure S4).
These results were confirmed by qualitative analysis of
isotopically labeled PA and AAA in cell lysates using high-
resolution MS (Figure S5), and activity of AASS was dem-
onstrated by 15N-glutamate enrichment studies. Increased
15N-glutamate enrichment in cells incubated with ε-15N-
lysine (Figure 3) confirms conversion of saccharopine to
AASA and glutamate as this involves transfer of ε-15N to
glutamate (Figure 1). This was detected in all cell types
investigated in this study, although absolute levels of enrich-
ment were shown to be rather low. This indicates that gluta-
mate production by the saccharopine pathway contributes
relatively little to overall glutamate production. In ATQ-
deficient fibroblasts, lower 15N-glutamate enrichment was
detected for cells incubated with α15N-Lys than in control
fibroblasts (Figure 3), indicating that the labeled glutamate
results from the transamination of AAA.
Interestingly, 15N-glutamate enrichment in cells incu-
bated in ε-15N-lysine containing media was higher in ATQ-
deficient fibroblasts than control fibroblasts suggesting
increased AASS activity in ATQ-deficient compared to con-
trol fibroblasts (Figure 3). Glutamine, used as a negative
control, did not exhibit enrichment beyond the natural abun-
dance of 0.7% 15N.
3.2 | Activity of the PA pathway in cultured
fibroblasts with impaired saccharopine
pathway
Furthermore, using isotopic tracing analysis, we examined
whether lysine degradation through the PA pathway is
increased when the first step of the saccharopine pathway is
FIGURE 3 Enrichment of 15N-labeled glutamine and glutamate in cell extracts. 15N-labeled glutamine and glutamate expressed as MPE (%) in
extracts of astrocytes, ReNcell CX NPCs and fibroblasts incubated in lysine-free media supplemented with Lys, α15N-Lys, or ε15N-Lys. The results
depicted are representative of at least two independent experiments performed in one cell line per cell type; however, similar results were obtained
with a second ATQ-deficient cell line. ATQ, antiquitin; Gln, glutamine; Glu, glutamate; MPE, molar percent enrichment; NPC, neural
progenitor cell
FIGURE 2 (A) Western blot showing expression of lysine degradation enzymes ATQ, PIPOX, and AASS in cultured human fibroblasts,
astrocytes, and ReNcell CX NPCs. (B) 15N-AAA in cell extracts. 15N-AAA expressed as MPE (%) in extracts of fibroblasts, astrocytes, and ReNcell
CX NPCs incubated in lysine-free media supplemented with Lys, α15N-Lys, or ε15N-Lys. Results are representative of at least two independent
experiments. AAA, α-aminoadipic acid; AASS, α-aminoadipic semialdehyde synthase; ATQ, antiquitin; MPE, molar percent enrichment; NPC,
neural progenitor cell; PIPOX, pipecolic acid oxidase
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impaired, using AASS-deficient fibroblasts, compared to
ATQ-deficient and control fibroblasts.
AASA/P6C and PA were not detectable in AASS-
deficient cells, whereas in ATQ-deficient cells, AASA/P6C
and PA concentrations were increased compared to control
fibroblasts. AAA concentrations were not higher in AASS-
deficient fibroblasts than background levels detected in
ATQ-deficient fibroblasts (Figure 4). Furthermore, in ATQ-
deficient fibroblasts, 15N-AASA/P6C and 15N-PA were pro-
duced only in cells supplemented with α15N-Lys therefore
derived exclusively from the saccharopine pathway
(Figure 4A and B). Furthermore and as expected, no enrich-
ment of 15N-glutamate to unlabeled glutamate was observed
in AASS-deficient fibroblasts (Figure S6). These results
illustrate that in fibroblasts, degradation of lysine does not
occur via the PA pathway even when the saccharopine path-
way is impaired.
4 | DISCUSSION
While it has long been reported that the PA pathway is the
predominant route of lysine degradation in the brain, a reap-
praisal of the importance of the saccharopine pathway in
brain is warranted. We examined the route of production of
AAA in human astrocytes and in a human NPC line derived
from the cortical region of human fetal brain (ReNcell CX
NPCs), which express AASS, PIPOX, and ATQ, but not in
neurons, as it has been shown that in human brain, neurons
do not express ATQ.20 Conclusions of our study are based
on the widely adopted hypothesis that the first step of the
PA pathway occurs via lysine α-transamination or
deamination.
Data generated within our study revealed that conversion
of lysine to AAA is only detectable through the saccharo-
pine pathway in cultured human astrocytes and human
NPCs, which is in line with the recent report that formation
of AAA in lysine degradation occurs by the saccharopine
pathway in mouse brain.13,14 Our isotopic tracing studies
showed conservation of the α-15N label in all lysine
FIGURE 4 Legend on next coloumn.
FIGURE 4 15N-labeled and unlabelled lysine catabolites in
fibroblast lysates. Concentrations of PA (A), AASA/P6C (B), and
AAA (C) in control, ATQ-deficient, and AASS-deficient fibroblasts
incubated in lysine-free media supplemented with 5% FCS and Lys,
α15N-Lys or ε15N-Lys, as indicated. For all metabolites, the limit of
detection and the limit of quantification were estimated at 0.004 μM
(S/N = 3) and 0.013 μM (S/N = 10), respectively. The results depicted
are representative of at least two independent experiments performed in
one cell line per cell type; however, similar results were obtained with
a second ATQ-deficient cell line. AAA, α-aminoadipic acid; AASA,
α-aminoadipic semialdehyde; AASS, α-aminoadipic semialdehyde
synthase; ATQ, antiquitin; PA, pipecolic acid
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degradation products detected. Glutamate enrichment studies
also demonstrated transfer of the ε-15N to glutamate, indicat-
ing conversion of saccharopine to AASA and glutamate as
previously shown in mouse cerebellar and cerebral slices.24
As such we confirmed ε-deamination or transamination of
lysine (the saccharopine pathway) as an active route of
lysine degradation in human astrocytes and NPCs.
In view of our findings, previous research results deserve
special consideration. In 1954, Rothstein and Miller reported
that in rat, PA and AAA were derived only from the PA
pathway and not through the saccharopine pathway of lysine
degradation.25 This was deduced from analysis of urine after
IP injection of α15N- or ε15N-DL-lysine and was based on
the assumption that L-PA derived from L-lysine; however, it
was later shown that L-PA is metabolized not only from L-
lysine but also D-lysine3,16 by D-amino acid oxidase.19
Therefore, the formation of AAA by the PA pathway in this
study cannot be attributed only to L-lysine degradation and
may have resulted from degradation of D-lysine.
It was subsequently reported that the saccharopine path-
way of degradation is active in tissues such as liver and
kidney,2–4,26–28 but that the PA pathway is the predominant
pathway in brain. The importance attributed to the PA path-
way in brain was deduced from the inability to detect sac-
charopine in lysine degradation in rat brain in early studies,3
low expression of AASS in mammalian brain compared to
liver, heart, and kidney,3,4,18,27,29 and the decrease in AASS
enzyme activity in the first week of postnatal life.28 Sacchar-
opine has since been detected in several studies in mouse
brain,13,14,18 and it has been proposed that the difficulty in
detecting saccharopine in early studies may have been due
to time of sampling,13,14 as well as the lower efficiency of
lysine conversion to saccharopine by saccharopine dehydro-
genase than the conversion of saccharopine to AASA by
lysine-oxoglutarate reductase, resulting in low concentra-
tions of saccharopine.30 In mammals, the bifunctional
enzyme AASS possesses activities of both these
enzymes.31,32
Furthermore, the detection of PA as a lysine degradation
product in brain was considered evidence of activity through
the PA pathway of lysine degradation.3 However, a recent
study in ATQ-deficient fibroblasts showed that PA can be
produced by the saccharopine pathway,5 and this was also
shown to occur in mouse brain, although more PA was pro-
duced by the PA pathway as shown by higher 15N-PA
enrichment in brain from ε-15N-lysine and α-15N-lysine trea-
ted mice.13,14,18 Our data in human astrocytes support and
extend previous findings in human fibroblasts showing that
PA is produced via the saccharopine pathway, by P6C con-
version to PA.5 This indicates species differences in the con-
version of L-lysine to PA by the PA pathway, as this was
detected in mouse but not in human cells.
We also showed that in fibroblasts with impaired sac-
charopine pathway activity due to AASS deficiency, there
was still no detectable production of PA or AAA by the PA
pathway.
Preliminary findings suggest that AASS activity in ATQ-
deficient fibroblasts could be increased compared to control
fibroblasts, as shown by glutamate enrichment studies
(Figure 3). This may indicate feedback inhibition by AAA
or a downstream metabolite and increased rate of lysine deg-
radation through the saccharopine pathway in ATQ defi-
ciency. Future studies investigating ATQ deficiency in
human brain cells would be important to extend these find-
ings to brain, as any increase in AASS activity due to ATQ
deficiency would further support the potential benefits of
inhibiting AASS (and therefore preventing AASA accumu-
lation) in ATQ deficiency.
5 | CONCLUSIONS
Our study provides the first evidence that the saccharopine
pathway is the main route for lysine degradation to AAA in
human astrocytes and a human NPC line derived from the
cortical region of human fetal brain (ReNcell CX NPCs),
and extends previous data in human fibroblasts. Results of
our experiments in addition to previous studies indicate spe-
cies differences in the activity of steps of the lysine degrada-
tion pathway. In mouse, PA is produced by both α- and
ε-deamination, while in all human cells investigated to date,
PA is only produced by ε-deamination. Recognition of the
relevance of the saccharopine pathway of lysine degradation
in human brain tissue may have been delayed due to differ-
ing activity of each step of the PA and saccharopine path-
ways depending on species, tissue as well as age-dependent
effects.28 While future studies using astrocyte-neuronal co-
cultures may provide further information on possible shut-
tling of lysine degradation products between neurons and
astrocytes, our findings indicate the importance of the sac-
charopine pathway in human brain cells, supporting the idea
that inhibition of the saccharopine pathway could offer new
treatment options for ATQ deficiency.
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